[A24-78] Entrectinib (solid tumours with a neurotrophic tyrosine receptor kinase [NTRK] gene fusion, > 1 month to < 12 years) – Benefit assessment according to §35a Social Code Book V
Last updated 04.11.2024
Project no.:
A24-78
Commission:
Commission awarded on 31.07.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Paediatric patients (1 month to less than 12 years of age) with solid tumours that have a neurotrophic tyrosine receptor kinase gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior neurotrophic tyrosine receptor kinase inhibitor, and who have no satisfactory treatment options other than larotrectinib
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A24-78_en
| Project no. | Title | Status |
|---|---|---|
| A20-74 | Entrectinib (solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-75 | Entrectinib (NSCLC) - Benefit assessment according to §35a Social Code Book V | Commission completed |